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Epidemics of infectious diseases have always been 
well documented throughout human history, 
particularly in ancient Egypt and Greece, and for 
diseases like smallpox, leprosy, tuberculosis, 
meningococcal infections, and diphtheria. Since 
ancient times, the morbidity and mortality of these 
infectious diseases have profoundly shaped the 
politics, commerce, culture, and social structure of 
different eras in epidemics.1 With the beginning of 
2020, the world has encountered a new challenge, with 
the name of Covid-19. Commencing from Wuhan city 
of China, this disease spread like wildfire within a 
matter of next few months, with a rising death toll and 
serious consequences on the entire globe. The impact 
of COVID-19 on the population was no less than terror 
and shock. Since COVID-19 disease kept on spreading 
via aerosol and droplet infections, World Health 
Organization (WHO) declared an emergency and 
along with other health agencies emphasized 
respiratory hygiene i.e. covering the nose and mouth 
with a mask and using cough etiquettes in addition to 
standard precautionary measures. Social distancing 
was emphasized. Different rapid treatment guidelines 
were developed and practiced across the globe, with 
no definitive management guaranteeing the recovery 
cent percent. Where a number of interventions were 
being tried and tested, attention was diverted towards 
vaccination since it had always been contemplated to 
be the integral in control of many infectious diseases.2 
Vaccination is envisaged as one of the most effective 
public health interventions for preventing and saving 
lives from different infectious diseases and promoting 
good health. Hence scientists from all over the world 
got involved in the rapid and expeditious 
development of vaccines against this novel disease 
According to WHO, different immunization programs 
prevent between 2 to 3 million deaths every year 
across all age groups. Since the advent of vaccination, 
as a preventive measure for communicable disease, its 
use has eradicated some of the most dreadful diseases 
from the world, the eminent example being smallpox.  
The main purpose of mass vaccination against any 
disease is to eradicate, eliminate or control it. 
Eradication of a disease means that disease and its 
causal agent are removed worldwide for example 
eradication of smallpox. Elimination of disease refers 
that the disease has disappeared from one WHO 
region but remains elsewhere like Polio Myelitis. The 
target was the eradication of Polio and we are almost 
there, whereby Polio almost nearly has been 
eradicated from the world, but its prevalence still 
affecting two countries is not attributed to the failure 
of the vaccine itself, but various geopolitical and social 
factors are responsible for thwarting our success. 
Containment or control of disease means that a point 
has been achieved that a particular disease no longer 
constitutes a significant public health problem.3 If we 
look into disease pattern so far, eradication or 
elimination of the COVID-19 disease from the globe 
appear to be elusive at present but containment of the 
disease should be our primary and foremost aim; 
whether we will be able to achieve herd immunity 
against COVID-19 or not? This question is yet to be 
answered.  
We can define a successful vaccination program like 
the one which achieves its aims in terms of disease 
control. Attainment of this goal and the impact of any 
vaccination program depends on a number of factors 
like vaccine coverage, vaccine efficacy, effectiveness, 
and herd immunity. Vaccine coverage is defined as a 
percentage of the target population who has been fully 
vaccinated against a disease. Vaccine efficacy gives an 
estimate of how much a vaccine reduces the risk of 
development of a disease in persons vaccinated versus 
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those who received a placebo, established from the 
evidence acquired from clinical trials. Vaccine 
effectiveness is an estimate of the direct protection of a 
vaccine under ordinary conditions of a public health 
program. And lastly, herd immunity also known as 
population immunity is an indirect effect of 
vaccination in a group of communities due to reduced 
disease transmission.4 This is particularly important to 
protect people at increased risk for severe illness from 
COVID-19, such as healthcare providers, older or 
elderly adults, and people with other medical 
conditions. 
Nevertheless, we should also be mindful of ‘vaccine 
failure’ defined as the development of disease despite 
being vaccinated against it. It may be primary vaccine 
failure where an individual fails to produce an 
adequate immune response to initial vaccination or 
secondary vaccine failure where a person 
accomplishes adequate initial response but then the 
immunity wanes over time.  
The world had been witnessing for over a century 
now, the lengthy procedures and time invested in the 
development of a successful vaccine featured by 
various phases; Phase 1 trials for safety in adult 
volunteers, following Phase 2 trials for 
immunogenicity and reactogenicity in the target 
population and ultimately proceeding for Phase 3 
trials intended to evaluate and establish protective 
efficacy and safety of any vaccine. All the above-
mentioned protocols and procedures have been taken 
into account for COVID-19 vaccines too but very 
hastily, giving precedence to urgent and swift 
production, basically owing to the lethal and dreadful 
nature of COVID-19 claiming human lives brutally 
involving many frontline health workers across the 
globe. Till now results are encouraging, however long-
term safety of these vaccinations is still awaited.  
Many existent, as well as new techniques, have been 
used in the development of different vaccines with the 
availability of one group of vaccines in a certain part 
of the world and another group of vaccines in another 
part of the world, with no clear-cut guidelines by 
health professionals.  So far many types of vaccines 
have been developed by different techniques in 
different countries and a worldwide campaign of 
vaccination has been initiated. Moreover, preferences 
and regulations by different countries regarding the 
use of a particular vaccine also make people confused 
regarding its administration. The general population 
was initially reluctant for vaccination even in the 
developed countries, but with the passage of time 
people of all classes of society are showing their 
willingness and acceptance. 
In Pakistan, the COVID-19 vaccination campaign 
started with the availability of the Sinopharm vaccine 
in February 2021. Health agencies of Pakistan had to 
put a lot of effort and different motivational drives 
were introduced and put into practice to get people 
vaccinated. Since the beginning of disease many 
clinical guidelines have been developed and exercised 
by different health authorities but since no definitive 
treatment is yet available, so old-time tested proverb, 
“prevention is better than cure” deems fits in the 
situation.5 
We should be grateful to science and technology that 
we have so many choices available regarding the 
vaccines, even though there are still uncertainties and 
concerns regarding the side effects and unforeseen 
consequences. Several different types of potential 
vaccines for COVID-19 have been developed and 
marketed, (Table 1) and many more are in 
developmental phases, all are designed to teach the 
body’s immune system to safely recognize and block 
the virus that causes COVID-19 including; Whole 
Virus vaccines, that use an inactivated or weakened 
form of the virus that doesn’t cause disease, but still 
generates an immune response e.g. Sinopharm and 
Sinovac. Protein-based vaccines use harmless 
fragments of proteins or protein shells that mimic the 
COVID-19 virus to safely generate an immune 
response e.g. Novavax vaccine. Then there are Viral 
vector vaccines that use a safe virus that cannot cause 
disease but serves as a platform to produce 
coronavirus proteins to generate an immune response 
e.g. Oxford -Astra Zeneca vaccines. And finally, RNA 
or mRNA vaccines, a cutting-edge approach that uses 
genetically engineered RNA or DNA to generate a 
protein that itself safely prompts an immune response 
e.g. Pfizer, BioNTech, and Moderna vaccines.6 
Whichever is the type of vaccine, we should not forget 
that mass vaccination of the population will result in 
achieving a high level of herd immunity to attain 
disease control. People of various communities 
behaved differently regarding the acceptance of this. 
SARS-CoV-2 coronavirus is a rapidly mutating virus, 
with four variants of concern i.e., Alpha, Beta, 
Gamma, and Delta virus; the delta presently is 
believed to be most the transmissible and highly 
infectious strain of COVID-19. This means that 
achieving herd immunity is even becoming more 
difficult. An infection rate of the original strain of 
SARS-CoV-2 was estimated to be 3 and 67 percent of 
the population was needed to be immunized to attain 
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herd immunity, however, the estimated infection rate 
by delta variant of this virus is assumed to be 6, and 
vaccination of 83 percent if the community is required 
to achieve the population immunity. 
As clinicians, we must be clear, no vaccination is 
considered entirely safe. Although a few common side 
effects are likely to occur and will be emerging during 
field trials and they may vary in frequency and 
severity because of changes in potential methods of 
manufacture storage or administration alteration in 
the target population. 
The general population including health care 
professionals is yet confused about which vaccination 
is better than the other and so on. It is important that 
till now no large definitive head-to-head trials of these 
vaccinations are available regarding this, so the broad 
message is that so ever vaccination is available may be 
taken instead of waiting for the invention of a new 
ideal or perfect one. We must not forget that in present 
times when there is an inequitable distribution of 
vaccines and other health-related resources across the 
globe especially in lower and middle-income 
countries, we are fortunate to have various types 
available in our country. Whichever vaccines we have 
available, we must receive them because we are in a 
state of combat against the COVID-19 pandemic, and 
these vaccines are the only single weapons have, for 
the nonce….  
 
 
Table 1: An overview of different COVID-19 vaccines being administrated in different parts of world 
Name of Vaccine Type Origin Efficacy Remarks 
Pfizer mRNA BionTech & Pfizer, 
Germany, United 
States 
91.3% SE: Mild to moderate pain, 
Fatigue, Headache, Rare 
allergic reactions 
Authorized for full and 
emergency use. 
Moderna mRNA US NIAID & 
BARDA 
94.1% SE: Pain at sight of injection, 
Headache, Joint pain, Rare 
Allergic reaction 
Authorized for 12 years and 
older. 





78.1% to 100%  
 
SE: Pain at sight of injection, 
Headache, Mild symptoms  
WHO approved  the use of this 







NA Authorized on 9 June 2021 in 
China. 
CoronaVac/SinoVac CIV Sinovac Biotech 
China 
66% to 90%  
 
June 1, 2021 for emergency 
use. 
Most widely used vaccine till 
July 2021, across World. 
Covaxin CIV Bharat Biotech, 
India 
64% to 93% - 




in phase II 
trials. 
Approved on Feb 2021 in 
Russia 
CovIran Barakat CIV Iran, Shifa 
Pharmed 
93.8% Approved in IRAN 
Minhal-Kangtai CIV Shenzan Kangtai, 
China 
NA 14 May, 2021 Authorized for 
emergency use. 
QazVac CIV RIBS, Kazakhstan NA Not approved yet 
WiBP-CorV CIV Developed by 72.8% to 100%  - 
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Sinopharm, China 




79%  - 




90%  World’s first combination 
vector vaccine 
 Registered by 11th August, 
2020 in Russia. 




61% to 76% SE: Pain at the sight of 
injection, Headache, Nausea, 
Rare risk of blood clotting 
Should not be administered to 
patients with capillary leak 
syndrome 




65.7% to 91% 
 
Approved for full and 








66% to 100% SE: Headache, Nausea, Pain at 
the injection site 
Approved in UK and US 






EpiVac Corona Protein Subunit 
Vaccine 
Russia NA Launched in November, 2020 




NA Approved for Emergency used 
in Taiwan 
Soberana Protein Subunit 
Vaccine 
Cuba 62%  - 
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